Feng C K, Chan K H, Liu K N, Or C H, Lee T Y
Department of Anesthesiology, General Veterans Hospital-Taipei, Taiwan, R.O.C.
Acta Anaesthesiol Sin. 1996 Jun;34(2):61-7.
Laryngoscopy and tracheal intubation are known to increase sympathetic activity that may be detrimental to patients with pre-existing ischemic or hypertensive heart diseases. In order to alter the hyperdynamic consequences resulting from intubation during induction of general anesthesia, we chose esmolol, an ultra-short acting cardioselective beta-adrenergic blocker, to attenuate the cardiovascular responses during tracheal intubation in patients undergoing elective surgery. The efficacy of esmolol in this regard was carefully evaluated.
Eighty ASA physical status class I or II patients undergoing elective, non-cardiac procedures were included in a randomized, single-blinded study consisting of 4 groups with each group receiving a designated drug: group A received normal saline as control, while group B, group C and group D received lidocaine 2 mg/kg, fentanyl 3 micrograms/kg and esmolol 2 mg/kg, respectively. Monitoring included EKG, pulse oximetry, capnometry and arterial pressure. All patients were premedicated with diazepam 0.1 mg/kg 30 min before induction of general anesthesia. Each designated drug was given upon induction of anesthesia (time zero). Anesthesia was induced with thiopental 5 mg/kg and succinylcholine 1.5 mg/kg, and maintained with N2O, 1% isoflurane in 50% O2 and vecuronium. Intubation was carried out 3 min after the designated drug was given. Heart rate (HR) and systolic arterial blood pressure (SBP) were obtained every min for 10 min after induction. Either chi-square test or analysis of variances (ANOVA) was used for statistical comparison. A p value less than 0.05 was considered statistically significant.
There was no difference in the demographic data among the four groups. After intubation, the incidence of tachycardia (HR > 100/min) was found in 3 of 20 (15%) patients in esmolol group, significantly lower than 17 of 20 (85%) patients in the control group, 15 of 20 (75%) patients in lidocaine group, and 11 of 20 (55%) patients in fentanyl group, respectively (p < 0.05). The incidence of hypertension (SBP > 180 mmHg) was found in 4 of 20 (20%) patients in esmolol group, significantly lower than 16 of 20 (80%) patients in control group and 14 of 20 (70%) patients in lidocaine group, respectively (p < 0.05), but not in 8 of 20 (40%) patients in fentanyl group. Besides, the incidence of hypertension in fentanyl group (40%) was significantly lower than control group (80%; p < 0.05), but not in lidocaine group (70%).
Results of this study showed that only esmolol could reliably offer protection against the increase in both HR and SBP, low dose of fentanyl (3 micrograms/kg) prevented hypertension but not tachycardia, and 2 mg/kg lidocaine had no effect to blunt adverse hemodynamic responses during laryngoscopy and tracheal intubation.
已知喉镜检查和气管插管会增加交感神经活动,这可能对已有缺血性或高血压性心脏病的患者有害。为了改变全身麻醉诱导期间插管引起的高动力反应,我们选择了艾司洛尔,一种超短效的心脏选择性β-肾上腺素能阻滞剂,以减轻择期手术患者气管插管期间的心血管反应。我们仔细评估了艾司洛尔在这方面的疗效。
80例美国麻醉医师协会(ASA)身体状况分级为I或II级的择期非心脏手术患者被纳入一项随机、单盲研究,该研究分为4组,每组接受一种指定药物:A组接受生理盐水作为对照,而B组、C组和D组分别接受2mg/kg利多卡因、3μg/kg芬太尼和2mg/kg艾司洛尔。监测包括心电图、脉搏血氧饱和度、二氧化碳监测和动脉压。所有患者在全身麻醉诱导前30分钟用0.1mg/kg地西泮进行术前用药。每种指定药物在麻醉诱导时(时间零点)给予。用5mg/kg硫喷妥钠和1.5mg/kg琥珀酰胆碱诱导麻醉,并用氧化亚氮、50%氧气中1%异氟烷和维库溴铵维持麻醉。在给予指定药物3分钟后进行插管。诱导后10分钟内每分钟记录心率(HR)和收缩动脉血压(SBP)。采用卡方检验或方差分析(ANOVA)进行统计学比较。p值小于0.05被认为具有统计学意义。
四组患者的人口统计学数据无差异。插管后,艾司洛尔组20例患者中有3例(15%)出现心动过速(HR>100次/分钟),显著低于对照组20例患者中的17例(85%)、利多卡因组20例患者中的15例(75%)和芬太尼组20例患者中的11例(55%)(p<0.05)。艾司洛尔组20例患者中有4例(20%)出现高血压(SBP>180mmHg),显著低于对照组20例患者中的16例(80%)和利多卡因组20例患者中的14例(70%)(p<0.05),但芬太尼组20例患者中的8例(40%)未出现。此外,芬太尼组的高血压发生率(40%)显著低于对照组(80%;p<0.05),但低于利多卡因组(70%)。
本研究结果表明,只有艾司洛尔能可靠地预防HR和SBP的升高,低剂量芬太尼(3μg/kg)可预防高血压但不能预防心动过速,2mg/kg利多卡因对喉镜检查和气管插管期间的不良血流动力学反应无抑制作用。